DOP013: Definition of therapeutic response criteria using MRI in Crohn’s Disease patients treated with anti-TNF therapy: A multicenter prospective study (the IRMA study)ECCO'17 Barcelona 2017
1
DOP014: Transmural healing is better than mucosal healing in Crohn's DiseaseECCO'17 Barcelona 2017
1
DOP015: International differences in gastroenterologists’ perspective on stopping therapy for patients with Crohn’s DiseaseECCO'17 Barcelona 2017
1
DOP016: Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of Inflammatory Bowel Diseases: Results from the multicenter European TEDDY studyECCO'17 Barcelona 2017
1
DOP017: Patterns of anti-TNF use and associated treatment outcomes in Inflammatory Bowel Disease patients: Results from an analysis of Dutch health insurance claims dataECCO'17 Barcelona 2017
1
DOP018: Effect of adalimumab on extraintestinal manifestations among patients with Ulcerative Colitis in a clinical practice setting: Results from INSPIRADAECCO'17 Barcelona 2017
1
DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s Disease: A GEMINI 2 post hoc analysisECCO'17 Barcelona 2017
1
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumabECCO'17 Barcelona 2017
1
DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn’s Disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension studyECCO'17 Barcelona 2017
1
DOP022: Vedolizumab (VDZ) and anti-α treatment effectiveness in patients with IBD treated in Germany: A retrospective chart reviewECCO'17 Barcelona 2017
1
DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active Ulcerative Colitis: Results from the US VICTORY consortiumECCO'17 Barcelona 2017
1
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infectionsECCO'17 Barcelona 2017
1
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAIDECCO'17 Barcelona 2017
1
DOP026: Sustained remission with vedolizumab in patients with Moderately to Severely active Ulcerative Colitis: A GEMINI 1 post hoc analysis of Week 14 remittersECCO'17 Barcelona 2017
1
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn’s Disease patients: A multicenter retrospective experienceECCO'17 Barcelona 2017
1
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatmentECCO'17 Barcelona 2017
1
DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: Post-hoc analysis of the taxit trialECCO'17 Barcelona 2017
1
DOP030: Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn’s Disease: A dual centre ‘real world’ studyECCO'17 Barcelona 2017
1